Mean platelet volume as an inflammation marker in active pulmonary tuberculosis by Gulsah Gunluoglu et al.
Gunluoglu et al. Multidisciplinary Respiratory Medicine 2014, 9:11
http://www.mrmjournal.com/content/9/1/11ORIGINAL RESEARCH ARTICLE Open AccessMean platelet volume as an inflammation marker
in active pulmonary tuberculosis
Gulsah Gunluoglu1*, Esra Ertan Yazar1, Nurdan Simsek Veske1, Ekrem Cengiz Seyhan2 and Sedat Altin1Abstract
Background: The mean platelet volume (MPV) reflects the size of platelets. It has been shown to be inversely
correlated with level of the inflammation in some chronic inflammatory diseases. This prospective study aims to show
the usability of MPV as an inflammation marker in patients with active pulmonary tuberculosis (PTB) by comparison
with healthy controls. In addition, its relationships with other inflammatory markers such as C-reactive protein (CRP)
and the erythrocyte sedimentation rate (ESR) as well as with the radiological extent of disease were examined.
Methods: This study included 82 patients with active PTB and 95 healthy subjects (control group). Whole blood
counts, CRP level, and ESR were compared between the two groups. In the PTB group, the relationships between the
radiological extent of disease and the MPV and other inflammation markers were investigated.
Results: The MPV was 7.74 ± 1.33/μL in the PTB group and 8.20 ± 1.13/μL in the control group (p = 0.005). The
blood platelet count, CRP level, and ESR were significantly higher in the active PTB group than in the control
group (p < 0.0001). In the PTB group, CRP levels (r = 0.26, p = 0.003) and ESR (r = 0.39, p = 0.003), but not MPV
(p = 0.80), were significantly correlated with the radiologic extent of the disease.
Conclusions: The MPV was lower in patients with PTB than in healthy controls, however, the difference was
limited. The MPV does not reflect the severity of the disease. The use of MPV as an inflammation marker and a
negative acute-phase reactant in PTB does not seem to be reliable.
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Tuberculosis (TB) is a common infectious disease caused
by Mycobacterium tuberculosis (Mtb), and it remains an
important public health problem despite developments in
its diagnosis and treatment. According to a World Health
Organization report, TB caused the death of 1,4 million
people worldwide in 2010 [1]. Delayed diagnosis and
treatment are also important public health issues. The
only definitive diagnostic method known for pulmonary TB
(PTB) is the growth of Mtb bacilli from pulmonary material
(sputum or bronchoscopic lavage fluid) [2]. Although
no other current test is more reliable for determining
the activity of PTB than culture growth of bacilli, some
biochemical parameters that reflect the inflammation
present in patients with this condition may provide guid-
ance at the diagnostic stage.* Correspondence: gunluoglugulsah@yahoo.com.tr
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article, unless otherwise stated.TB is an infectious disease characterised by a cellular
immune response. Mtb and its components activate mac-
rophages and lymphocytes, which then secrete cytokines
(TNF-α, IL-6, IL-8, and IL-12) enabling the development
of a cellular immune response [3,4]. Of these cytokines,
TNF-α and IL-6 in particular affect maturation of thrombo-
poietic cells and secretion of platelets into the circulation
[5]. The CRP level, ESR, and presence of reactive thrombo-
cytosis can also reportedly be used to determine the disease
activity, and these values are correlated with the disease
severity [6-8].
The mean platelet volume (MPV) reflects the size of
platelets. It can be measured during a routine automatic
whole blood count. The MPV has been shown to correlate
with the function and activation of platelets [9-11]. The im-
portance of MPV has been emphasized as an inflammation
marker in some chronic inflammatory disorders, such
as inflammatory intestinal diseases, rheumatoid arth-
ritis, and ankylosing spondylitis. An inverse correlationtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Comparison of age, sex, smoking habit and BMI






Gender, n (male/female) 65/30 54/28 >0.05
Age (median±SD) 36±9.96 26.5±1.16 0.05
Smokers n (%) 39 (41.1%) 44 (53.7%) >0.05
BMI (median±SD) 24±3.5 20.6±2.8 <0.0001
BMI; Body mass index, SD; standard deviation.
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strated [12-15].
This study aims to show the usability of the MPV as
a readily obtainable negative inflammation marker that
can be measured during a routine whole blood count
for assessment of disease activity in patients with active
PTB by comparison with healthy controls. This study also
investigates the relationships between MPV and other
inflammatory markers (ESR and CRP level) as well as
the radiological extent of the disease.
Methods
This prospective study was performed in accordance with
the principles of the Declaration of Helsinki and approved
by the Ethics Committee of Yedikule Chest Diseases and
Thoracic Surgery Training and Research Hospital.
Patients who presented to the outpatient clinic of our
hospital between June 2013 and September 2013 and
were diagnosed with PTB based on clinical symptoms,
radiological signs, and examination of sputum smears
and cultures for Mtb were included in the study. Healthy
subjects who presented to the outpatient clinic for rou-
tine examination, and presented no disease and normal
lung radiography findings during the examination, were
included in the study as control group.
The exclusion criteria were: age < 18 or > 60 years,
acute or chronic infection, systemic arterial hypertension,
endocrinological disorders, haematological disease, heart
failure, hepatic and renal disorders, cancer, and peripheral
vascular disease [16]. None of the enrolled subjects had
received anticoagulant medications, nonsteroidal anti-
inflammatory drugs, or contraceptives.
Detailed histories of all patients and healthy subjects
were obtained, and their smoking status were noted.
A physical examination of all participants was performed,
and weights and heights were measured to calculate
their body mass index (BMI). Chest X-rays were also
performed. Venous blood was drawn from all participants
(pre-treatment samples in patients with PTB). The blood
samples were placed in tubes containing EDTA. A whole
blood count analysis was carried out within 120 min to
assess the MPV (μL) [17]. The Cell-Dyn 3700 haemato-
logyanalyser (Abbott Laboratories) was used for this
analysis. The values obtained at the end of the analysis
were recorded. Serum CRP levels (normal, 0–5 mg/L)
were measured using an Olympus AU2700 plus analyser
(Beckman Coulter, Tokyo, Japan), and the ESR (60 min)
was determined using an Eriline AR analyser (Linear
Chemicals, Barcelona, Spain).
The disease was categorised according to its radio-
logical extent in patients with PTB based on the criteria
by Dlugovitzky et al. [18]. Accordingly, the extent was
classified as mild disease (single-lobe involvement and no
visible cavities or pleural involvement), moderate disease(unilateral involvement of two or more lobes with a solitary
cavity, or mild extent plus pleural involvement or effusion),
or severe disease (bilateral involvement and multiple
cavities, or moderate extent plus pleural involvement
or effusion).
The blood platelet counts, MPVs, serum CRP levels,
and ESRs in the patient and healthy groups were compared.
In addition, the relationship between the radiological extent
of disease and inflammation markers were assessed in the
patient group.
Statistics
The data were entered into the SPSS analysis software.
A chi-square test was used to compare frequencies, and
Student’s t-test was used to compare averages. Pearson’s
correlation test was used to show correlations between con-
tinuous variables, and Spearman’s correlation test was used
for correlation analyses involving non-parametric variables.
Results
The study group comprised 82 patients with active PTB
and 95 healthy subjects. The participants’age, sex, smoking
habits, and BMI are shown in Table 1. The mean age, sex
distribution, and number of individuals with smoking
habits showed no statistically significant differences be-
tween the two groups. The BMI was lower in patients with
active PTB than in the healthy controls, and the difference
was statistically significant. No significant correlation was
found between MPV and BMI (p = 0.103). The MPV
was significantly lower in the active PTB group than in
the control group (p = 0.005).
The levels of the other investigated inflammatory markers
also differed between the two groups (Table 2).
The correlation between MPV and platelet count was
analysed. In patients with PTB, there was an inverse re-
lationship between these parameters, but it was not
statistically significant (p = 0.8). In the healthy control
group, on the other hand, there was a moderate (r = 0.25)
and statistically significant (p = 0.015) inverse correlation
between MPV and platelet count.
No significant relationship was found between the
radiological extent of disease and the platelet count in
patients with PTB (p = 0.24). Also, no correlation was
found between the MPV and radiological extent of disease
Table 2 Comparison of level of MPV and the other
inflammatory markers in the healthy subjects and
tuberculosis patients groups
Healthy subjects Tuberculosis patients P value
MPV (mean±SD) 8.2±1.13 7.74±1.33 0.005
PLT (mean±SD) 269±70.50 404±146.70 <0.0001
CRP (mean±SD) 10.06±12.70 64.68±53.82 <0.0001
ESR (mean±SD) 2.47±3.51 54.47±28.69 <0.0001
MPV; mean platelet volume, PLT; platelet count, CRP; C-reactive protein, ESR;
erythrocyte sedimentation rate, SD; standard deviation.
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between platelet count and CRP level (r = 0.60, p = 0.0001)
and ESR (r = 0.64, p = 0.0001). Additionally, there were
significant correlations between the radiological extent
of disease and CRP level (r = 0.26, p = 0.003) and ESR
(r = 0.39, p = 0.003).
Discussion
Active TB has been associated with an imbalance of the
Th1/Th2 cytokine pattern. Effective induction of Th1
immunity is vital in the defence against Mtb. The major
cytokines secreted in response to Mtb are IL-2, IFN-
gamma, IL-6, IL-12, and TNF-α [19,20]. Animal models
have demonstrated the presence of cytokines in TB granu-
lomas. In addition, human studies have shown IL-1 beta,
IL-6, and TNF-α, which are secreted from active macro-
phages in the bronchoalveolar lavage fluid of patients with
active TB [21]. Nevertheless, a systemic inflammatory
response is known to occur in patients with TB when
these cytokines enter the systemic circulation, and as a
result the CRP blood level and ESR increase.
Platelets are pulmonary immune cells as shown by their
role in the pathogenesis in some pulmonary diseases and
their immune cell characteristics [22,23]. In patients
affected by PTB microthromboses form in vessels around
the tuberculous cavities, probably as a defence mechanism
[24]. These thromboses prevent the spread of Mtb, thus
averting the occurrence of disseminated disease. Reactive
thrombocytosis is seen in many chronic inflammatory
diseases, including TB [7,25,26]. The increased number
of platelets in patients with PTB has also been linked
to the disease extent, which supports the above patho-
logical changes [27,28].
The MPV reflects the size of platelets and is a marker
used to determine platelet function. The size of platelets
in the circulation is associated with the intensity of inflam-
mation [16]. In some chronic inflammatory disorders, the
MPV has been used as an inflammatory marker of disease
activity and to monitor the response to anti-inflammatory
treatment [12,15,29]. In acute exacerbations of chronic
obstructive pulmonary disease, in which the intensity of
inflammation also increases, the MPV has been found
to be significantly lower while the serum leukocyte countand neutrophil percentage were higher than those during
the stable period. It has been suggested that the MPV
can be used as a negative acute-phase reactant [30]. When
various cytokines, including IL-6, enter the systemic circu-
lation in patients with TB, systemic symptoms emerge and
an acute-phase response occurs [4,7,31]. In such cases of
TB, the lower MPV can be explained by the fact that
megakaryopoiesis is affected by the excess production of
proinflammatory cytokines and acute-phase reactants
which decreases the size of platelets, therefore smaller
platelets are released from the bone marrow [9]. Similarly,
Baynes et al. [25] found the MPV to be low in patients
with active PTB and suggested that although thrombopoi-
esis increased in patients with TB, the platelets’ lifetime
may have been shortened. Platelets and their indices in ac-
tive PTB have been addressed in several previous studies
[6,26,27,32]. Contrary to our study, Tozkoparan et al. [6]
found that the MPV was significantly higher in patients
with active TB than in control patients with inactive TB
and non-specific pneumonia and decreased with anti-TB
treatment. On the other hand, Sahin et al. [27] showed
that in patients with active TB MPV was identical to that
of patients with non-specific pneumonia and healthy sub-
jects. There was no correlation between MPV and radio-
logical extent of TB in a study of Sahin et al. as in our
work. However, Tozkoparan et al. found a weak correlation.
Disease-specific characteristics and cardiovascular risk fac-
tors (diabetes, hypertension, smoking, obesity, etc.) may dir-
ectly affect the MPV [16]. This is why participants with risk
factors were excluded from the study. In the above men-
tioned studies there were not enough data about the pa-
tients’ characteristics that could have affected the MPV.
Contradictory results may be related to the characteristics
of the studied groups of patients. An association has been
established between obesity and high MPV, and a positive
correlation has been demonstrated between BMI and MPV
[33,34]. As expected, in our study BMIin the PTB patients
was lower than in healthy controls but no relationship was
found between BMI and MPV (p = 0.103).
CRP is an acute-phase reactant secreted from hepatocytes
in response to tissue damage or inflammation. It has been
shown to increase in proportion to the severity of TB and
decrease after treatment [35]. It has also been linked to
mortality [36]. The ESR, another acute-phase reactant, has
been found to be high in patients with active PTB and to
have a correlation with the radiological extent of disease
[8]. Our study also demonstrated that the CRP level and
ESR increased significantly in active disease and had a posi-
tive correlation with the radiological extent of the disease.
Conclusions
In conclusion, in our study the MPV, measured auto-
matically during a whole blood count, in patients with
active PTB was lower than in healthy controls. However,
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is limited and smaller than the difference between CRP
levels or ESRs of patients and those of healthy controls.
The MPV had no correlation with thrombocytosis, acute-
phase reactants or the radiological extent of the disease.
Therefore, it does not reflect the disease severity. MPV
does not seem to be reliable as an inflammation marker to
determine the disease activity in patients with PTB and as
a negative acute-phase reactant. Thus, further prospective
studies on this issue with the inclusion of larger numbers
of patients are mandatory.
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